Luc Girard

Active 1995–2025

109
Papers
22,690
Citations
82
h-index
106
i10-index

Citations

Citations per year for Luc Girard1921: 1 citations1976: 1 citations1986: 1 citations1995: 2 citations1997: 12 citations1998: 12 citations1999: 11 citations2000: 18 citations2001: 30 citations2002: 51 citations2003: 43 citations2004: 42 citations2005: 129 citations2006: 151 citations2007: 227 citations2008: 277 citations2009: 252 citations2010: 308 citations2011: 283 citations2012: 248 citations2013: 294 citations2014: 239 citations2015: 284 citations2016: 276 citations2017: 273 citations2018: 240 citations2019: 762 citations2020: 819 citations2021: 838 citations2022: 687 citations2023: 473 citations2024: 722 citations2025: 338 citations2026: 6 citations1922–1975: no citations, so these years are not shown1977–1985: no citations, so these years are not shown1987–1994: no citations, so these years are not shown1996: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,553 citing papers, 32.1% of this breakdownChina: 1,540 citing papers, 13.9% of this breakdownUnited Kingdom: 554 citing papers, 5% of this breakdownGermany: 492 citing papers, 4.4% of this breakdownJapan: 472 citing papers, 4.3% of this breakdownItaly: 404 citing papers, 3.7% of this breakdownFrance: 351 citing papers, 3.2% of this breakdownSpain: 335 citing papers, 3% of this breakdownCanada: 319 citing papers, 2.9% of this breakdownSouth Korea: 267 citing papers, 2.4% of this breakdownAustralia: 231 citing papers, 2.1% of this breakdownNetherlands: 200 citing papers, 1.8% of this breakdown
0%32.1%Other 21.2%

Fields

  • Biochemistry, Genetics and Molecular Biology46.6%
  • Medicine44.4%
  • Immunology and Microbiology3.3%
  • Pharmacology, Toxicology and Pharmaceutics1.2%
  • Computer Science0.9%
  • Neuroscience0.7%
  • Other2.9%

Topics

  • Lung Cancer Treatments and Mutations5.6%
  • Lung Cancer Research Studies3.8%
  • RNA modifications and cancer3.2%
  • Epigenetics and DNA Methylation3.2%
  • Cancer Genomics and Diagnostics3.1%
  • Cancer Cells and Metastasis2.8%
  • Other78.3%

Coauthors

All papers

Open in search
  1. Co-occurring Genomic Alterations Define Major Subsets of KRAS -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Waun Ki Hong, John D. Minna, James P. Allison, P. Andrew Futreal, Jing Wang, Ignacio I. Wistuba, John V. Heymach - Cancer Discovery 2015 cited by 916

  2. ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs

    Authors: , , , , , , , , , , - Cell Reports 2016 cited by 530

  3. An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ignacio I. Wistuba, Kevin R. Coombes, John D. Minna, John V. Heymach - Clinical Cancer Research 2012 cited by 1,121

  4. Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes

    Authors: , , , , , , , , , , - Translational Lung Cancer Research 2018 cited by 281

  5. Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2012 cited by 571

  6. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2017 cited by 314

  7. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers

    Authors: , , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2014 cited by 283

  8. SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures

    Authors: , , , , , , , , , , , , , , , , , , - Cell Reports 2020 cited by 168

  9. A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Cancer 2020 cited by 169

  10. Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Molecular Cell 2019 cited by 231

  11. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Metabolism 2020 cited by 146

  12. AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yang‐Xin Fu, John D. Minna, Rolf A. Brekken - Cell Reports Medicine 2022 cited by 94

  13. Acquired Cross-Resistance in Small Cell Lung Cancer due to Extrachromosomal DNA Amplification of MYC Paralogs

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2024 cited by 61

  14. 27-Hydroxycholesterol Promotes Cell-Autonomous, ER-Positive Breast Cancer Growth

    Authors: , , , , , , , , , , , , , - Cell Reports 2013 cited by 355

  15. Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kevin R. Coombes, Noelle S. Williams, David A. Wheeler, John B. MacMillan, Ralph J. DeBerardinis, Michael G. Roth, Bruce A. Posner, John D. Minna, Hyun Seok Kim, Michael A. White - Cell 2018 cited by 150

  16. Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Communications Biology 2021 cited by 101

  17. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies

    Authors: , , , , , , , , , , , , , - Clinical Cancer Research 2023 cited by 66

  18. Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene Discovery

    Authors: , , , , , , , , , , , - PLoS ONE 2009 cited by 798

  19. ZEB1 drives epithelial-to-mesenchymal transition in lung cancer

    Authors: , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2016 cited by 346

  20. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by β-lapachone

    Authors: , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2007 cited by 351

  21. Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis

    Authors: , , , , , , , , , , , , , , , , - Cancer Research 2018 cited by 86

  22. Evasion of Innate Immunity Contributes to Small Cell Lung Cancer Progression and Metastasis

    Authors: , , , , , , , , , , , , , - Cancer Research 2021 cited by 83

  23. Tumor Cells Modulate Macrophage Phenotype in a Novel In Vitro Co-Culture Model of the NSCLC Tumor Microenvironment

    Authors: , , , , , , , , - Journal of Thoracic Oncology 2022 cited by 52

  24. Immortalization of Human Bronchial Epithelial Cells in the Absence of Viral Oncoproteins

    Authors: , , , , , , , , , , , , , , , , , , , , - Cancer Research 2004 cited by 670